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Abstract
Background: De novo missense variants in CDK13 have been described as the cause of syndromic congenital heart
defects in seven individuals ascertained from a large congenital cardiovascular malformations cohort. We aimed to
further define the phenotypic and molecular spectrum of this newly described disorder.
Methods: To minimise ascertainment bias, we recruited nine additional individuals with CDK13 pathogenic variants
from clinical and research exome laboratory sequencing cohorts. Each individual underwent dysmorphology exam
and comprehensive medical history review.
Results: We demonstrate greater than expected phenotypic heterogeneity, including 33% (3/9) of individuals without
structural heart disease on echocardiogram. There was a high penetrance for a unique constellation of facial
dysmorphism and global developmental delay, as well as less frequently seen renal and sacral anomalies. Two
individuals had novel CDK13 variants (p.Asn842Asp, p.Lys734Glu), while the remaining seven unrelated individuals had a
recurrent, previously published p.Asn842Ser variant. Summary of all variants published to date demonstrates apparent
restriction of pathogenic variants to the protein kinase domain with clustering in the ATP and magnesium binding sites.
Conclusions: Here we provide detailed phenotypic and molecular characterisation of individuals with pathogenic variants
in CDK13 and propose management guidelines based upon the estimated prevalence of anomalies identified.
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Background
Congenital heart defects, facial dysmorphism and intel-
lectual developmental disorder (CHDFIDD) is a newly
described syndrome caused by de novo variants in
CDK13 [1]. The syndrome was discovered as part of a
large exome sequencing cohort of 1891 individuals with
congenital heart defects. All seven initially reported chil-
dren had structural congenital heart disease with either
atrial and/or ventricular septal defects or pulmonary
valve abnormalities. Individuals were reported to have a
recognisable facial gestalt characterised by a small mouth,
thin upper lip, posteriorly rotated ears, epicanthal folds,
upslanted palpebral fissures and hypertelorism. All indi-
viduals had global developmental delay and/or intellectual
disability. Brain imaging abnormalities included agenesis
of the corpus callosum and aplasia of the cerebellar ver-
mis. A subsequent report identified additional individuals
with de novo variants in CDK13 that reached genome-
wide significance in a second large exome sequencing
cohort of 4293 families containing individuals with de-
velopmental disorders [2]. However, dysmorphology and
organ-specific detailed phenotypic information was not
available.
CDK13 encodes a 1512 amino acid protein kinase in-
volved in the regulation of gene expression by control-
ling the phosphorylation status and activity of splicing
regulators [3, 4]. It is part of a family of 20 different
ATP-dependent serine-threonine protein kinases re-
gulating cell-cycle progression and gene expression [5].
CDK12 and CDK13 are thought to have evolved by
duplication of a common gene ancestor; however, both
kinases appear to operate in separate complexes in
mammalian cells [6, 7]. In developing mouse embryos,
Cdk12 and Cdk13 regulate axonal elongation [8], sug-
gesting an important role in neuronal development. All
pathogenic variants in CDK13 to date are clustered in
the highly conserved serine-threonine kinase domain
with molecular modelling predicting perturbation of ei-
ther ATP binding, magnesium binding or interaction
with cyclin K [1].
Although CDK13-related CHDFIDD was initially thought
to be an extremely rare disorder, 20 patients have been
identified in less than one year from initial disease gene
discovery [1, 2]. Here, we aim to provide the first detailed
phenotypic summary of CDK13-related CHDFIDD ascer-
tained through clinical and research exome sequencing
pipelines.
Methods
Participants
This study was approved by the Baylor College of Medicine
Institutional Review Board for Human Subjects Research.
The initial individual was diagnosed by exome sequencing
after enrolment in the Undiagnosed Diseases Network at
the Baylor College of Medicine Clinical Site. In order to
provide comprehensive phenotypic and molecular charac-
terisation, additional individuals with CDK13 pathogenic
variants were recruited from clinical exome sequen-
cing laboratory cohorts and one individual was ascer-
tained through review of the Baylor-Hopkins Center
for Mendelian Genomics (BHCMG) exome variant
database. We received informed consents to proceed
with publication for nine unrelated individuals. Eight
of the nine individuals underwent dysmorphology
exam by an American Board of Medical Genetics and
Genomics board-certified physician. Comprehensive
medical records, including physical exam findings, la-
boratories, imaging studies, developmental status and
disease natural history were reviewed. When possible,
original laboratory reports or imaging studies were ob-
tained for review.
DNA preparation and sequence analysis
In all nine individuals, CDK13 variants were initially de-
tected by exome sequencing. In eight individuals, the
remaining extracted DNA was used to perform Sanger
sequencing confirmation. In one individual (Individual
1009), no additional extracted DNA was available, but
the exome data were manually reviewed and considered
to be reliable for inclusion (24 variant reads out of 53
total reads). For Sanger sequencing, venous blood sam-
ples were collected for DNA extraction from peripheral
blood leukocytes (PBL). Total genomic DNA was ex-
tracted with the Puregene DNA extraction kit (Gentra
Systems, Inc. Minneapolis, MN, USA) according to the
manufacturer’s protocol. Genomic DNA from each indi-
vidual was used for polymerase chain reaction (PCR)
amplification with primer design dependent upon variant
genomic location. PCR amplification was performed for
35 cycles from 50 ng of total genomic DNA extracted
from PBL. All PCR products were purified. Direct se-
quence analysis of PCR products was performed in both
the forward and reverse directions using automated fluor-
escence dideoxy sequencing methods. Sequencing profiles
were inspected visually to detect heterozygous changes.
The base numbering refers to the A of the ATG start
codon as position 1 and the nomenclature is based on the
convention recommended by the Human Genome Vari-
ation Society. A variant was determined to be de novo if it
was not present in either maternal or paternal samples.
Results
Genotype
Nine individuals were found to have missense substi-
tutions in highly conserved amino acid positions of
CDK13. Eight of the nine patients were confirmed to
have de novo variants. Parental samples were unavailable
for Individual 1009, who had a previously described
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pathogenic variant (c.2525A > G). No genotype–pheno-
type correlations were found between variant location
and severity or spectrum of disease manifestations; how-
ever, the number of individuals enrolled in this study
limited the power of this analysis.
Seven of nine patients shared the same variant
(c.2525A > G, p.Asn842Ser), previously reported as
pathogenic [1, 2]. Two missense changes (c.2524A > G,
p.Asn842Asp and c.2200A > G, p.Lys734Glu) are novel
de novo variants. Each of these variants perturbs an
amino acid residue previously reported in a pathogenic
variant [1, 2], but results in different amino acid sub-
stitutions. None of the variants were found in ExAC or
gnomAD databases (accessed on 17 June 2017). Nucleo-
tide variant, predicted protein alteration, zygosity and
variant history are summarised in Table 1. Those va-
riants previously reported are accompanied by PMID
reference in Table 1. No additional pathogenic, likely
pathogenic or de novo variants were reported in any of the
clinical laboratory exome sequencing reports (Additional
File 1: Table S1).
Including this report, there are 29 individuals with
CDK13 pathogenic variants [1, 2] and this report], with
27 proven de novo and two of unknown inheritance,
secondary to unavailable parental samples. All variants
are predicted to impact the protein kinase domain
(amino acids 697–1029), with clustering in the ATP-
binding and magnesium-binding sites as demonstrated
in Fig. 1. More than half of the variants (15/29) perturb
the wild-type asparagine residue at amino acid position
842, suggesting its importance in magnesium inter-
action. The absence of loss-of-function variants com-
bined with the clustering of missense variants within a
single protein domain in affected individuals suggests a
possible gain-of-function disease mechanism.
Phenotype
Phenotypic characterisation was performed by medical
history, imaging, laboratory and dysmorphology review.
Medical records were reviewed comprehensively with
the goal of better understanding the clinical spectrum of
CDK13-related CHDFIDD. Facial examination for po-
tential dysmorphology was performed for all patients
with available photographs and is summarised in Table 2.
Several highly penetrant facial features were identified in
the majority of patients, suggesting a potentially recog-
nisable pattern or ‘facial gestalt’. A few of the patients
(n = 3) had been previously suspected to have Kabuki syn-
drome, demonstrating the similarity to this condition. The
distinctive facial features of CDK13-related CHDFIDD
include hypertelorism, epicanthal folds, highly arched eye-
brows, wide nasal bridge, short columella, thin upper lip
and abnormal ears. All patients had at least three key
features and 92% had four or more of these seven key
Table 1 Genotype results. All individuals (1001–1009) were found to have CDK13 variants initially by either research or clinical
exome sequencing
Sex, ID Age (years) Nucleotide variant Protein alteration De novo Zygosity Variant history (PMID)
F, 1001 2 c.2524A > G p.N842D Yes Het Novel variant
F, 1002 8 c.2525A > G p.N842S Yes Het 27479907
M, 1003 4 c.2525A > G p.N842S Yes Het 27479907
M, 1004 2 c.2525A > G p.N842S Yes Het 27479907
F, 1005 14 c.2525A > G p.N842S Yes Het 27479907
F, 1006 2 c.2525A > G p.N842S Yes Het 27479907
M, 1007 17 c.2525A > G p.N842S Yes Het 27479907
M, 1008 0.5 c.2200A > G p.K734E Yes Het Novel variant
M, 1009 38 c.2525A > G p.N842S Unknown Het 27479907
F, 265645a 7 c.2525A > G p.N842S Yes Het 27479907
F, 265813a 0.2 c.2525A > G p.N842S Yes Het 27479907
F, 259460a 3 c.2525A > G p.N842S Yes Het 27479907
M, 262889a 8 c.2149G > A p.G717R Yes Het 27479907
F, 271894a 5 c.2140G > C p.G714R Yes Het 27479907
F, 258830a 12 c.2252G > A p.R751Q Yes Het 27479907
M, 270818a 1 c.2525A > G p.N842S Yes Het 27479907
Where possible, all variants were confirmed by Sanger sequencing. Note that a paternal sample was not available for ID 1009, thus de novo status is unknown.
Age refers to age at last assessment
Het heterozygous, novel not previously published
For previously reported variants the PMID is provided. Isoform: NM_003718
aPreviously published with DECIPHER ID [1]
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features, suggesting that this condition typically presents
with a consistent and potentially recognisable constella-
tion of dysmorphic features, as illustrated in Fig. 2. In
addition, ear abnormalities were universally present and
included low-set positioning, posterior angulation, over-
folded helices and various simplified morphologies with
cupping (Fig. 3a).
Strabismus (69%), abnormal tone including hypotonia
(69%) or spasticity (15%), and musculoskeletal abnormal-
ities (62%) were commonly observed (Table 2). Although
sacral anomalies were present on examination in a mi-
nority of patients (n = 4), the unusual nature of the
manifestations may help in syndrome recognition. Sacral
abnormalities ranged from simple dimples or sacral
clefting, to spina bifida, to a striking bony sacral promi-
nence with apical slit as seen in Fig. 3b.
Table 3 summarises the cardiac, brain, renal and skeletal
abnormalities and provides details regarding growth and
development. All patients had gross motor and language
delays and were diagnosed with either developmental
delay or intellectual disability. The degree of intellectual
impairment ranged from mild to severe. Several had poor
weight gain or short stature. Four patients had microce-
phaly. Among those who had brain MRI, central nervous
system abnormalities were almost universal (10/11) and
included periventricular gliosis (n = 3), dysgenesis of the
corpus callosum (n = 4), spinal cord syrinx (n = 2), cerebel-
lar tonsillar abnormalities (n = 2) and diminished white
matter volume (n = 1). Renal abnormalities seen in three
patients included duplicated collecting systems, dilated
collecting systems and fused renal ectopia. Spinal ab-
normalities were observed in 31% (5/16) of individuals,
ranging from scoliosis or hyperlordosis (n = 3) to one indi-
vidual who had multiple cervical spinal fusions and a large
haemangioma of the L1 vertebral body. Loose or hyper-
mobile joints were reported in the majority of individuals;
however, due to a lack of objective criteria between exami-
ners, these findings were not aggregated in tabular form.
Since CDK13-related CHDFIDD was initially disco-
vered in a large exome sequencing congenital heart di-
sease cohort [1], all initial patients were selected for
study based upon their expressed cardiac disease. In our
series of nine patients, congenital cardiac disease was
present in two-thirds (6/9) of the individuals confirming
that it is a prominent, but not invariant, component of
the syndrome. In the remaining three individuals (1003,
1005, 1007; ages 4, 14 and 17 years, respectively), echo-
cardiograms did not reveal evidence for structural car-
diac disease. In aggregate, cardiac involvement was
present in 81% of individuals (13/16). Defects seen in
multiple patients include atrial septal defects (8/16),
ventricular septal defects (4/16), pulmonary valve ab-
normalities (2/16) and hypoplastic left pulmonary ar-
tery (2/16). One patient had Ebstein’s anomaly with an
abnormal tricuspid valve. It is important to note that
the oldest individual in this report (Individual 1009) is
Fig. 1 a CDK13 Domain Composition. Proline-rich (PRM), alanine-rich (AR), Arginine/serine-rich (RS), and serine-rich (SR) domains are indicated.
The protein kinase domains span amino acids 697–1029. Numbers below the schematic represent amino acid positions of various domains.
Domain data adapted from [10]. b Summary of 29 total pathogenic variants including this report. All variants are predicted to impact the
protein kinase domain with additional clustering in the ATP-binding and magnesium-binding sites. More than half (15/29) of the variants
perturb the wild-type asparagine residue at amino acid position 842. Asterisk indicates variants contributed by this study: (1) variants published
in [1]; (2) variants published in [2]. Variants present in more than one individual per publication are listed as ‘x #’
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38 years old and has left ventricular non-compaction and
sick sinus syndrome requiring pacemaker implantation,
after having initially presented as a child with bicuspid
aortic valve, aortic stenosis and aortic insufficiency. The
cardiomyopathy and electrical disturbance in the oldest
individual may suggest age-related penetrance of addi-
tional cardiac sequelae; however, phenotypic extrapolation
should be cautioned as these sequelae were only seen in a
single individual. Alternatively, the detection of left-
ventricular non-compaction in adulthood may be due to
improvements in imaging technology over time.
Additional low-frequency findings in our cohort that
are not included in tabular form include hypothyroidism
(n = 1), small chest circumference (n = 2), malignant
hyperthermia (n = 1), craniosynostosis (n = 2) and club
foot deformity (n = 2).
Discussion
After the recent discovery [1] of CDK13 as the cause of
congenital heart defects, facial dysmorphism and intel-
lectual developmental disorder (CHDFIDD), we aimed to
further delineate the phenotypic spectrum, dysmorphology
Fig. 2 Craniofacial and dysmorphology features in individuals with pathogenic CDK13 variants. Patients share a facial gestalt which in some cases
include hypertelorism, epicanthal folds, highly arched eyebrows, widened nasal bridge, short columella, thin upper lip and dysplastic ears. a Study
ID 1001. b Study ID 1004. c Study ID 1006. d Study ID 1005. e Study ID 1002. f Study ID 1008. g Study ID 1007. h Study ID 1003
Fig. 3 a Spectrum of ear abnormalities seen in individuals with CDK13 pathogenic variants. Ear abnormalities include over-folded superior helices,
posterior angulation, low-set ears and cupping. b An unusual sacral bony prominence with an apical vertical slit identified in Individual 1001
Bostwick et al. Genome Medicine  (2017) 9:73 Page 6 of 9
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and medical co-morbidities of this newly described syn-
drome. In order to minimise ascertainment bias, we took a
genotype-first approach and recruited nine additional un-
published individuals with CDK13 pathogenic variants
detected by clinical or research exome sequencing. Our re-
sults confirm that congenital heart disease, neurodevelop-
mental disorders and facial dysmorphisms are important
components. Emerging from this detailed phenotyping, we
emphasise the potential clinical significance of other organ
involvement including renal abnormalities, spinal and sacral
anomalies, and widen the spectrum for neurological struc-
tural abnormalities and cardiac abnormalities. We suspect
that the recurrent craniofacial dysmorphisms may reliably
constitute a recognisable facial gestalt. Interestingly, some
individuals in the series had previously been considered by
initial clinical examination to have features consistent with
Kabuki syndrome. Given the clinical feature overlap,
CDK13 genotyping should be considered in individuals
clinically suspected to have Kabuki syndrome but who lack
molecular confirmation. The compilation of these clinical
features and congenital anomalies affords an opportunity to
propose initial management suggestions based on the cal-
culated prevalence of multi-system involvement.
Proposed initial management upon diagnosis of CDK13-
related CHDFIDD
Given the prevalence of cardiac, neurological, renal, ocu-
lar and skeletal abnormalities in individuals with CDK13
pathogenic variants, consideration of echocardiogram,
brain MRI, renal ultrasound and ophthalmology eva-
luation are warranted in all patients after initial mole-
cular diagnosis. Although this study is limited by our
phenotypic sample size (n = 16), there is ample evidence
to recommend this minimum initial medical evaluation.
Additionally, any sacral abnormalities identified on phys-
ical exam should prompt additional evaluation including
sacral imaging as indicated. Given that developmental
delay was present in all individuals, therapies should be
initiated at the youngest possible age to maximise deve-
lopmental potential. Ascertainment of additional indi-
viduals and understanding the natural history of this
syndrome will further refine these proposed manage-
ment guidelines.
Increasing need for reverse clinical genomics
Historically, most disease gene discovery occurred after
the gathering of a large cohort of individuals with a re-
markably similar phenotype. It was common for a syn-
drome to be identified, named and well-delineated prior
to gene discovery. With the advent of next-generation
sequencing, many new gene discoveries are originating
from large disease-specific sequencing cohorts often
containing thousands of individuals. In these new stu-
dies, syndromes are identified first molecularly instead
of phenotypically. This experimental design has created
a new demand for ‘reverse clinical genomics’, where
disease-gene directed cohorts are then studied pheno-
typically to delineate the syndromic associations and ap-
propriate medical management. Recent papers [9] have
employed a similar approach, demonstrating the need for
subsequent detailed clinical evaluation as a prerequisite to
understanding the complete phenotypic spectrum.
Conclusions
Extensive phenotyping using a genotype-first approach
and aggregated clinical phenotyping information from
participants with pathogenic CDK13 variants enables
syndrome delineation and initial construction of clinical
management guidelines. We highlight the recognisable
facial characteristics, congenital and neurodevelopmental
anomalies and propose initial management guidelines
for this Mendelian disorder. The exome sequencing
rare variant data underscore the importance of disease-
associated pathogenic variant clustering around the
ATP-binding and magnesium-binding sites and empha-
sises that all reported pathogenic variants to date are
missense substitutions in the protein kinase domain.
Additional file
Additional file 1: Table S1. All pathogenic, likely pathogenic or de novo
variants identified on the clinical genetics laboratory report for Individuals
1001–1008. (PDF 450 kb)
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